PC
OTLK icon

PointState Capital’s Outlook Therapeutics OTLK Stock Holding History

PointState Capital’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,250
Closed -$850K – 152
2016
Q3 		$850K Hold
1,250
– – 0.01% 142
2016
Q2 		$680K Buy
+1,250
New +$746K 0.01% 99

Other funds holding OTLK

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PointState Capital's OTLK Position: Q4 2016 in Review

PointState Capital sold out of Outlook Therapeutics (OTLK) in Q4 2016, closing a stake of 1,250 shares — an estimated $850K sold.

PointState Capital first reported a position in OTLK in Q2 2016 and held it in 2 quarters. The position peaked at $850K in Q3 2016. 15 funds tracked by Wall St. Rank hold OTLK as of Q4 2016.

  • PointState Capital reported no remaining Outlook Therapeutics position as of Q4 2016 after selling out during the quarter.
  • PointState Capital sold 1,250 Outlook Therapeutics shares in Q4 2016, an estimated $850K.
  • PointState Capital first reported a position in Outlook Therapeutics in Q2 2016 and held it in 2 quarters.
  • PointState Capital's Outlook Therapeutics position peaked at $850K in Q3 2016.
  • 15 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2016.

Based on PointState Capital's 13F filing for Q4 2016, filed 14 Feb 2017.